Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone–tazobactam (6:1) vs (3:1) in acute lower respiratory and urinary tract infections
CTR20130987Phase 2Active
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceftriaxone + tazobactam in acute lower respiratory tract infection (LRTI), Acute Urinary Tract Infection (UTI), There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition., Ceftriaxone-resistant bacterial infection. Started Oct 2013; status: active.
02
Drugs
ceftriaxone + tazobactam
03
Conditions
acute lower respiratory tract infection (LRTI)Acute Urinary Tract Infection (UTI)There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition.Ceftriaxone-resistant bacterial infection
Beyond the preview
Go deeper on CTR20130987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130987.